Akademik Veri Yönetim Sistemi
POLISH JOURNAL OF PATHOLOGY, cilt.74, sa.1, ss.18-28, 2023 (SCI-Expanded, Scopus)
The aim of this study is to make a differential diagnosis and prognosis of the amp-ullary adenocarcinoma subtypes. We also investigated the role of prognostic mark-ers PD-1 and PD-L1, and epidermal growth factor receptor (EGFR). Local or locally advanced stage ampullary adenocarcinoma patients who had un-dergone pancreaticoduodenectomy at the time of diagnosis were included. MUC1, MUC2, MUC5AC, CDX2, CK7, CK20, PD-1, and PDL-1 were analysed immu-nohistochemically, and EGFR was analysed by real-time polymerase chain reaction. According to histopathological and immunohistochemical evaluation, we found 27 patients as pancreatobiliary type and 56 patients as intestinal type adenocar-cinoma. The median survival of patients with intestinal and pancreatobiliary type adenocarcinoma was 23 months and 76 months (p = 0.201), respectively. When the survival of PD1-positive (n = 23) and PD-L1-positive (n = 18) patients were compared with the patients with negative staining (n = 60, n = 65), no sig-nificant difference was found. Epidermal growth factor receptor mutation was de-tected in a total of 6 patients, and 5 of these 6 mutations were shown in intestinal type tumours and one in a pancreatobiliary type tumour. A significant difference was determined in terms of overall survival for the patients with EGFR mutations compared to those without (p = 0.008). In conclusion, we could reveal the prog-nostic significance of EGFR mutation, which is also a target molecule.